(AGENPARL) – gio 16 febbraio 2023 16 February 2023
EMA/65631/2023
Media and Public Relations
News announcement
Human medicines: highlights of 2022
In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 40 had a new active substance which had never been authorised in the European Union (EU) before. The [overview of the 2022 key recommendations](https://link.mediaoutreach.meltwater.com/ls/click?upn=eR8gA2rSMGyvDZC4ShthtIfMhRs-2BEGfuPOqTkc00h0GfjgRiltESIhCE-2BU9cRfr8wW0goRAG9Oh4TJXWFWdy15WR4rxH-2F7v7Jp6w2W125NTNWHXrZLZZ-2BQ4nRF6YCfSBHJeo_mLoYh0p4AWg4foFr5HgrZ1QioQ33bLwdnQ-2BsYGKFX9mv8wVBOgi5GpVq-2FNhlrfTlX9L-2BS1vA2QXwHmqtsL-2BrQOvRw3CzioWUrjOOTPQmRkGlFdW82nbIfwPJFbqZt34sdiqSAju7zmtlGDAqTSXyLk9vNokoGwTTHjeXBVVJNaaY9LrulR-2FStWrqoEtNYd724H0E0St6NSWA0rt-2FrJgjXzBTK-2BHXAZuDJZgI2TYH3Eoflhc-2Fnh-2BAGjQOp3PHXuQHQGCimQFueK3MDu6SUFpZ5P1GIYfNPO-2BcDeVQVRz6HnpbMyaNyizcPowQEPNu8hrh-2FDcxJfkR-2FARHjbcytSD5-2BVNj9Vul-2BbulSoNctewOxQleqO-2FJUs6JJQwIlAeFH4bTzEUTwI9UWoO6pBXcfZqMeg-3D-3D) published today includes figures on the authorisation of medicines and a selection of new treatments that represent significant progress in their therapeutic areas.
Public health emergencies remained a key priority for EMA in 2022. The highlights document summarises the most important recommendations on vaccines and treatments for COVID-19 and for mpox (monkeypox).
Once a medicine is authorised by the European Commission and prescribed to patients, EMA and the EU Member States continuously monitor its quality and benefit-risk balance and take regulatory action when needed. Measures can include a change to the product information, the suspension or withdrawal of a medicine, or a recall of a limited number of batches. An overview of some of the most notable safety-related recommendations is also included in the document.
Notes
– This press release, together with all related documents, is available on the Agency’s website.
– More information on the work of the European Medicines Agency can be found on its website: [www.ema.europa.eu](https://link.mediaoutreach.meltwater.com/ls/click?upn=nqMWBkcnaKM2j9uKfjWiRwTbpPcDFw8nzREeoKQGNbqpy3ZUpjhx3pulbu1WpVlE7G1f_mLoYh0p4AWg4foFr5HgrZ1QioQ33bLwdnQ-2BsYGKFX9mv8wVBOgi5GpVq-2FNhlrfTlX9L-2BS1vA2QXwHmqtsL-2BrQOvRw3CzioWUrjOOTPQmRkGlFdW82nbIfwPJFbqZt34sdiqSAju7zmtlGDAqTSXyLk9vNokoGwTTHjeXBVVJNaaY9LrulR-2FStWrqoEtNYd724H0E0St6NSWA0rt-2FrJgjX6OjMwN1geRjshznETbaY1STc2f9gEemcDSBtIsKOAlgPMbrvUC6lU6RwKNCu-2Fk1S2FVDsaTUdEVlFzuDvPWxOI0WADTuIvaD4ekIIHJwPGlLYB-2Bi7YR-2BLXDJgrhGW1YIHMHpe-2FMBKMZ2em9p9wqiRedT8qu22NY-2Fmp-2F-2FE58Gdf8XrVJTZP72AzIrOeod3ULww-3D-3D)
Contact
EMA press office